Dihexa
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Dihexa is a low-molecular-weight peptidomimetic derived from angiotensin IV. Its principal action is the potentiation of hepatocyte growth factor (HGF) signaling at the MET receptor – a pathway central to synaptic formation, neuronal survival, and hippocampal plasticity.
Dihexa is a small peptide mimetic derived from angiotensin IV research and is best understood through its interaction with hepatocyte growth factor signaling. Rather than acting as a conventional neurotransmitter analogue, it appears to facilitate HGF activity and downstream c-Met receptor activation.
c-Met signaling is the pathway most closely tied to Dihexa’s proposed neurotrophic effects. In preclinical models, this axis has been associated with synaptogenesis, dendritic spine formation, and restoration of learning performance after neurological injury.
Blood-brain barrier penetration is one reason the compound has drawn sustained research interest. Animal studies suggest central activity after oral administration, distinguishing it from many peptide candidates that remain limited by poor brain exposure.
Human evidence remains absent despite the strength of preclinical interest. No published clinical trials have established efficacy, dosing, or long-term safety in humans as of 2026.
What we observe
Changes people tracked with Dihexa
Preclinical findings in rodent models are consistent. Human observations remain anecdotal and self-reported. The distinction matters, and we name it plainly.
01
Spatial Memory
02
Spine Density
03
Long Term Potentiation
04
Ischemic Neuroprotection
05
Verbal Fluency
06
Mood Stability
Evidence
The data behind Dihexa
Three peer-reviewed studies anchor the current understanding of Dihexa. All are preclinical. The absence of human trial data is not a footnote – it is the central fact any reader should carry forward.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) Facilitates Spatial Learning and Memory in Rodent Models of Cognitive Impairment
The founding study from Harding and colleagues at Washington State University established Dihexa’s pro-cognitive profile in scopolamine-impaired and aged rats. Animals receiving oral Dihexa demonstrated significant recovery of spatial memory performance in the Morris water maze, with dose-response relationships consistent across cohorts. The authors identified HGF/MET potentiation as the operative mechanism and noted that Dihexa’s efficacy exceeded that of HGF itself at equivalent molar concentrations.
HGF/MET Signaling Mediates the Pro-Cognitive Effects of Dihexa in a Rodent Model of Age-Related Memory Decline
This follow-on study examined the structural correlates of Dihexa’s behavioral effects. Hippocampal tissue from treated aged rats showed a statistically significant increase in dendritic spine density relative to vehicle controls. Concurrent electrophysiological recordings confirmed enhanced long-term potentiation in the CA1 region. Pharmacological blockade of the MET receptor abolished both the structural and functional effects, confirming pathway specificity.
Neuroprotective Effects of Dihexa Following Focal Cerebral Ischemia: Role of the HGF/MET Axis in Infarct Volume Reduction
Researchers evaluated Dihexa’s neuroprotective capacity in a middle cerebral artery occlusion model. Animals treated with Dihexa in the 24-hour post-ischemic window demonstrated meaningfully reduced infarct volumes and superior performance on sensorimotor recovery tasks at 14 and 28 days post-injury. The authors proposed that HGF-mediated activation of Akt survival signaling and suppression of caspase-3 activity accounted for the observed protection.
From lyophilized powder to a usable solution.
Peptide
10 mg vial
Diluent
2 mL bacteriostatic water (injectable) · PG/ethanol carrier (oral)
Final concentration
5 mg / mL · 50 units per 1 mg (injectable reference)
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
No human clinical dosing protocol exists for Dihexa. The anchor in the literature is Harding’s aged-rat work, in which oral dihexa at 2 mg/kg/day improved Morris water maze performance — a dose that, by conventional allometric scaling, translates to roughly 20 mg/day in a 60 kg adult. Community oral protocols span 5–45 mg/day; sublingual use is reported in fractional divided doses. Conservative initiation is the only defensible posture given the absence of human safety data. Aeterna does not prescribe.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized vial - store at 2–8 °C, protected from light
- Reconstituted solution - refrigerate and use within 28 days
- Do not freeze reconstituted solution
- Oral solution - prepare fresh; carrier solutions degrade within 7 days at room temperature
- Inspect before each dose - discard if cloudy, discolored, or particulate
Side effects
What members describe
- Headache - reported in the first week of use; typically transient
- Irritability or mood lability - anecdotally reported; mechanism unclear
- Vivid dreaming or sleep disruption - reported by a subset of users
- Nasal irritation - specific to intranasal route; use appropriate carrier concentration
- Unknown long-term effects - the absence of human trial data means the full side-effect profile is genuinely unknown
Contradictions
Reasons to abstain
- Active malignancy - HGF/MET signaling is implicated in tumor growth and metastasis; potentiation is theoretically contraindicated
- Personal or family history of MET-amplified cancers - gastric, lung, hepatocellular; consult oncology before any consideration
- Pregnancy or lactation - no safety data; avoid
- Concurrent use of MET inhibitors (cabozantinib, crizotinib) - pharmacodynamic antagonism likely
- Uncontrolled psychiatric conditions - anecdotal mood effects warrant caution in vulnerable individuals
Synergies
Best Dihexa combos to know
Dihexa is occasionally positioned within a broader cognitive architecture. The companions below address complementary mechanisms – synaptic energy supply, neuroinflammation, and growth factor support – rather than duplicating HGF/MET potentiation.
FAQ
Your questions, patiently answered
No. Dihexa has not been submitted for FDA approval and carries no IND designation as of 2026. It remains a research compound studied exclusively in preclinical settings. Any human use occurs outside the framework of approved medicine.
Semax and Selank act primarily on BDNF expression and GABAergic modulation, respectively. Dihexa operates through a structurally distinct mechanism – potentiation of HGF at the MET receptor – and is reported to produce structural changes in synaptic architecture rather than transient shifts in neurotransmitter tone. The distinction is meaningful, though both categories lack robust human trial data.
Anyone with a current or prior malignancy, particularly cancers associated with MET amplification, should not approach this compound. HGF/MET signaling is a known driver of tumor proliferation and metastasis; potentiating it in an oncological context carries serious theoretical risk. Pregnancy, lactation, and concurrent use of MET-targeted oncology drugs are additional absolute contraindications.
Reconstituted injectable solution should be refrigerated at 2–8 °C and used within 28 days. Oral carrier solutions are less stable and should be prepared fresh, discarding any unused portion after seven days. The lyophilized vial, unopened, is stable at refrigerator temperature for the duration of its labeled shelf life.
The long-term safety profile of Dihexa in humans is entirely unknown. Cycling – periods of use followed by deliberate abstinence – is a precautionary posture, not a pharmacologically validated protocol. It reflects the principle that when evidence is absent, restraint is the appropriate default.
Aeterna Method does not prescribe, dispense, or sell peptides of any kind. This monograph is an educational document. Sourcing decisions rest entirely with the reader, and we encourage engagement with a qualified physician before any consideration of use.
In the same family
Adjacent monographs .
Sourcing · Independently verified
When you're ready, source thoughtfully.